

BCHCW CORPORATE GOVERNANCE COMMITTEE

**Wednesday, 17 June 2020 @ 1.15 pm
(Videoconference)**

AGENDA				
1	Welcome and apologies	Chair	1.15	-
2	Minutes from the previous meeting , including agreed actions	Chair	1.20	Doc 1
FOR DISCUSSION/DECISION		-		
3	A new citizen voice body update	Board Chair/ CEO	1.25	Doc 2 (a-d)
4	Accountability framework , including: <ul style="list-style-type: none"> ▪ Hosting Agreement ▪ BCHCW Standing Orders ▪ Model Standing Orders for CHCs 	CEO	1.35	Doc 3a Verbal (b) (c)
5	Impact of COVID-19 on our activities and ways of working , including: <ul style="list-style-type: none"> ▪ contingency arrangements ▪ temporary changes to Board and CHC policies and procedures ▪ Recovery planning: guide for CHCs on return to office working ▪ Staff & member well-being surveys ▪ ICT 6 month development plan ▪ Guide for CHCs on recruitment 	CEO/ CO	1.50	Doc 4 (a) (b) (c-d) (e) (f) (g-h)
6	Planning 2020-2021 , including <ul style="list-style-type: none"> ▪ June 2020 Board work programme ▪ Corporate Governance Committee annual work programme 	CEO/ CO	2.30	Doc 5 (a) (b)

	<ul style="list-style-type: none"> ▪ Standards & Performance Committee annual work programme ▪ Equality Plan outline 			(c) Verbal
7	Reporting 2020-2021 , including <ul style="list-style-type: none"> ▪ Annual reporting process ▪ Equality Report 2019-2020 update ▪ Welsh Language Standards annual reporting requirements 2019-2020 	CEO/ CO	2.50	Doc 6 (a) Verbal (b)
8	Communication tools, including updates on: <ul style="list-style-type: none"> ▪ A new website for the Board and CHCs ▪ Social media 	CEO/ CO	3.10	Doc 7
	FOR INFORMATION	-	-	-
9	Dealing with potential conflicts of interest: <ul style="list-style-type: none"> ▪ Updated declaration of interest register 	-	-	Doc 8
10	Deciding and responding to consultations, calls for evidence, etc: <ul style="list-style-type: none"> ▪ Response to the General Pharmaceutical Council's consultation on temporary changes 	-	-	Doc 9
	CLOSE	Chair	3.15	-